To assess the safety and tolerability of a single oral dose of the Capecitabine test and reference formulations

Intervention1: Capecitabine Tablets 500 mg, manufactured by Hetero labs ltd.: The recommended dose of capacitabine is 1250 mg/m2 administered orally twice daily (morning and evening; equivalent to 2500 mg/m2 total daily dose) for 2 weeks followed by a 1-week rest period given as 3 week cycles
Intervention2: Capecitabine Tablets 500 mg,manufactured by Hetero labs
ltd.: The recommended dose of capacitabine is 1250 mg/m2
administered orally twice daily
(morning and evening;
equivalent to 2500 mg/m2 total
daily dose) for 2 weeks followed
by a 1-week rest period given
as 3 week cycles
Control Intervention1: Xeloda (Capecitabine) Tablets 500 mg (Distributed by Genentech USA, Inc., A Member of the Roche Group, South San Francisco, CA 94080): The recommended dose of
XELODAÂ is 1250 mg/m2
administered orally twice daily
(morning and evening;
equivalent to 2500 mg/m2 total
daily dose) for 2 weeks followed
by a 1-week rest period given
as 3 week cycles
Primary outcome(s): Establishing the bioequivalence between test and referenceTimepoint: Day 1 and Day 2